Compare
Humacyte, Inc. vs Aligos Therapeutics, Inc. vs Scinai Immunotherapeutics Ltd. vs Inhibrx Biosciences, Inc.
| Latest fiscal year | Humacyte, Inc. HUMA | Aligos Therapeutics, Inc. ALGS | Scinai Immunotherapeutics Ltd. SCNI | Inhibrx Biosciences, Inc. INBX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.04M | $2.19M | $1.31M | $1.30M |
| Revenue growth (YoY) | n/a | -39.5% | +99.2% | +550.0% |
| Gross margin | -376.1% (computed) | n/a | -202.3% | n/a |
| Operating margin | n/m | n/m | -575.3% | n/m |
| Net margin | n/m | n/m | -633.6% | n/m |
| Net income | -$40.83M | -$24.19M | -$8.31M | -$140.06M |
| EPS (Diluted) | -$0.26 | -$2.45 | n/a | -$9.04 |
| Operating cash flow | -$105.04M | -$82.50M | -$6.03M | -$129.79M |
| Free cash flow | -$105.93M | n/a | -$6.05M | -$129.82M |
| Cash & equivalents | $50.50M | $18.30M | $1.66M | $124.22M |
| Total assets | $116.37M | $88.53M | $11.63M | $146.48M |
| Total liabilities | $113.26M | $34.99M | n/a | $138.49M |
| Shareholders' equity | $3.11M | $53.55M | $8.10M | $7.99M |
| Return on year-end equity | n/m | -45.2% | -102.5% | n/m |
| Shares outstanding | 193.00M | 6.18M | 13.87B | 14.58M |
Revenue, most recent five fiscal years
| Fiscal year | Humacyte, Inc. | Aligos Therapeutics, Inc. | Scinai Immunotherapeutics Ltd. | Inhibrx Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $2.04M Ended 2025-12-31 | $2.19M Ended 2025-12-31 | $1.31M Ended 2025-12-31 | $1.30M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $3.61M Ended 2024-12-31 | $658.0K Ended 2024-12-31 | $200.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $6.19M Ended 2023-12-31 | n/a | $1.80M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | n/a |